Trending Stock News

Sachem Head Capital Management LP Boosted Holding in Cdk Global (CDK) by $65.68 Million; Concert Pharmaceuticals (CNCE) Valuation Declined While Bvf Trimmed by $29.14 Million Its Stake

CDK Global, Inc. (NASDAQ:CDK) Logo

Bvf Inc decreased its stake in Concert Pharmaceuticals Inc (CNCE) by 37.17% based on its latest 2017Q4 regulatory filing with the SEC. Bvf Inc sold 1.17 million shares as the company’s stock declined 14.38% with the market. The hedge fund held 1.97 million shares of the health care company at the end of 2017Q4, valued at $50.96M, down from 3.14M at the end of the previous reported quarter. Bvf Inc who had been investing in Concert Pharmaceuticals Inc for a number of months, seems to be less bullish one the $445.15M market cap company. The stock increased 0.58% or $0.11 during the last trading session, reaching $19.16. About 119,795 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 26.05% since April 22, 2017 and is uptrending. It has outperformed by 14.50% the S&P500.

Scott Ferguson increased its stake in Cdk Global Inc (CDK) by 72.83% based on its latest 2017Q4 regulatory filing with the SEC. Sachem Head Capital Management Lp bought 925,000 shares as the company’s stock declined 11.91% with the market. The hedge fund run by Scott Ferguson held 2.20M shares of the miscellaneous company at the end of 2017Q4, valued at $156.46 million, up from 1.27M at the end of the previous reported quarter. Sachem Head Capital Management Lp who had been investing in Cdk Global Inc for a number of months, seems to be bullish on the $8.78 billion market cap company. The stock decreased 0.15% or $0.1 during the last trading session, reaching $65.21. About 483,305 shares traded. CDK Global, Inc. (NASDAQ:CDK) has declined 2.80% since April 22, 2017 and is downtrending. It has underperformed by 14.35% the S&P500.

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals had 24 analyst reports since August 12, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Monday, September 18 report. Aegis Capital maintained it with “Buy” rating and $2500 target in Monday, June 12 report. The firm has “Buy” rating given on Wednesday, September 9 by Aegis Capital. As per Friday, January 12, the company rating was maintained by Stifel Nicolaus. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Buy” rating given on Tuesday, September 22 by TH Capital. Roth Capital maintained the stock with “Buy” rating in Tuesday, September 22 report. As per Wednesday, August 9, the company rating was maintained by H.C. Wainwright. As per Friday, July 1, the company rating was initiated by Stifel Nicolaus. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Buy” rating given on Thursday, June 29 by Aegis Capital. As per Monday, November 9, the company rating was downgraded by UBS.

Investors sentiment increased to 2.62 in Q4 2017. Its up 1.44, from 1.18 in 2017Q3. It is positive, as 10 investors sold CNCE shares while 19 reduced holdings. 42 funds opened positions while 34 raised stakes. 15.49 million shares or 6.32% more from 14.57 million shares in 2017Q3 were reported. Eam Invsts Llc reported 74,232 shares stake. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Management Corporation has 12,700 shares for 0% of their portfolio. California Pub Employees Retirement Systems reported 85,000 shares. Moreover, Panagora Asset Mgmt has 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 37,220 shares. Vanguard Group Inc Inc, Pennsylvania-based fund reported 776,375 shares. Franklin Resource Inc accumulated 602,600 shares. Tiaa Cref Investment Mngmt Ltd Liability accumulated 0% or 173,457 shares. Quantbot Tech Lp stated it has 0.02% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Bnp Paribas Arbitrage reported 3,722 shares stake. Millennium Mgmt Lc owns 725,885 shares. Moreover, Great Point Prns Ltd Com has 2.96% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Federated Invsts Inc Pa holds 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) or 21,923 shares. Clarivest Asset Ltd reported 14,318 shares or 0.01% of all its holdings. State Of New Jersey Common Pension Fund D has 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 40,000 shares. First Quadrant Lp Ca owns 37,814 shares.

Since January 16, 2018, it had 0 buys, and 6 insider sales for $2.60 million activity. 31,236 Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares with value of $597,833 were sold by ALDRICH RICHARD.

Analysts await Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings on May, 1. They expect $-0.61 EPS, down 1.67% or $0.01 from last year’s $-0.6 per share. After $-0.26 actual EPS reported by Concert Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 134.62% negative EPS growth.

Bvf Inc, which manages about $999.89 million and $829.55M US Long portfolio, upped its stake in Regulus Therapeutics Inc (NASDAQ:RGLS) by 1.03 million shares to 13.97 million shares, valued at $14.53 million in 2017Q4, according to the filing. It also increased its holding in Forward Pharma A/S by 2.00 million shares in the quarter, for a total of 3.46 million shares, and has risen its stake in Cytokinetics Inc (NASDAQ:CYTK).

Sachem Head Capital Management Lp, which manages about $1.04B and $2.16 billion US Long portfolio, decreased its stake in Dell Technologies Inc by 2.66M shares to 450,000 shares, valued at $36.58 million in 2017Q4, according to the filing. It also reduced its holding in Microsoft Corp (NASDAQ:MSFT) by 690,000 shares in the quarter, leaving it with 3.36M shares, and cut its stake in Comcast Corp New (NASDAQ:CMCSA).

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *